Physician profile
Kara J Way
NPI 1982047940
$71,733.35
in general payments reported to CMS, 2019-2025
54 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $1,919 · 2021: $23K · 2022: $21K · 2023: $1,732 · 2024: $6,862 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,896 · Travel and Lodging: $2,833 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,306.58 |
| Food and Beverage | $7,895.64 |
| Travel and Lodging | $2,832.59 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21,099.74 | 2021 | |
| Pfizer INC. | $18,593.90 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18,540.27 | 2022 | |
| Abbvie INC. | $1,938.22 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Novartis Pharmaceuticals Corporation | $1,933.00 | 2019-2025 | |
| Mdd US Operations, LLC | $988.40 | 2022-2025 | Gocovri, Apokyn, Xadago |
| Amneal Pharmaceuticals LLC | $962.38 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Amgen INC. | $766.68 | 2019-2025 | Uplizna, Aimovig |
| Biogen, INC. | $617.82 | 2019-2025 | Vumerity, Spinraza, Qalsody |
| Lilly USA, LLC | $605.83 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $604.19 | 2019-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $564.66 | 2020-2025 | Xcopri |
| Genzyme Corporation | $456.68 | 2019-2024 | |
| Ucb, INC. | $443.74 | 2021-2025 | Zilbrysq, Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $352.40 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.